Streetbeat News

Analyst Ratings

SNPX

Synaptogenix, Inc. (NASDAQ:SNPX) has announced the publication of a peer-reviewed paper detailing the results of a Phase 2 clinical trial for Bryostatin-1, a drug developed for the treatment of Alzheimer's disease. The trial demonstrated statistically significant benefits of Bryostatin-1 in advanced Alzheimer's patients, with no significant cognitive decline observed over a 10-month period. The trial was sponsored by the National Institute on Aging (NIA) and the National Cancer Institute (NCI), both part of the NIH.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:17 pm

WSR

JMP Securities analyst Mitch Germain has reiterated a 'Market Outperform' rating on Whitestone REIT (NYSE:WSR) and maintained a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:13 pm

RIVN

Baird has added Rivian Automotive to its 'Fresh Pack', predicting that the company's Q3 deliveries will exceed consensus estimates. Baird is bullish on Rivian (RIVN) ahead of the Q3 delivery report.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:13 pm

SHOP

JMP Securities analyst Andrew Boone has reiterated a Market Outperform rating on Shopify (NYSE:SHOP) and maintained a $72 price target.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:11 pm

LPRO

JMP Securities analyst David Scharf has reiterated a Market Outperform rating on Open Lending (NASDAQ:LPRO) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:09 pm

AAPL

Gene Munster, founder of Deepwater Asset Management, predicts that Apple Inc. (NASDAQ:AAPL) will reduce its dependence on China over the next decade, shifting production to India. He anticipates that China's share of Apple's revenue will decline from 40-45% to 25-30% over the next five years, with India's revenue surpassing that of Greater China. Apple is also expected to start producing AirPods in India, with the overall value of products manufactured in the country projected to increase fivefold over the next four to five years, reaching $40 billion.

Portfolio Pulse from Shanthi Rexaline

September 26, 2023 | 1:08 pm

JAMF

JMP Securities analyst Joey Marincek has reiterated a Market Outperform rating on Jamf Holding (NASDAQ:JAMF) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:07 pm

CRWD

JMP Securities analyst Trevor Walsh has reiterated a Market Outperform rating on CrowdStrike Holdings (NASDAQ:CRWD) and maintained a price target of $235.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:03 pm

CHRS

Four analysts have given bullish ratings for Coherus BioSciences (NASDAQ:CHRS) in the last quarter, with an average price target of $18.0, implying an upside from the current price of $4.05. This average has decreased by 21.74% from the previous average price target of $23.00.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 1:01 pm

JPM

UUP

JPMorgan Chase & Co. CEO Jamie Dimon has warned of potential economic turmoil if Federal Reserve benchmark interest rates were to rise to 7%. He believes such a scenario could lead to a financial stress test of epic proportions. This warning has resonated with market sentiment, as the U.S. dollar, tracked through the Invesco DB USD Index Bullish Fund ETF, surged. Economists already place a 60% probability of a U.S. recession within the next year.

Portfolio Pulse from Piero Cingari

September 26, 2023 | 1:01 pm